Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Thermo Instrument

This article was originally published in The Gray Sheet

Executive Summary

Thermo Instrument: Completes acquisition of most of the Fisions Scientific Instruments Division from Rhone-Poulenc Rorer for [pound]122 mil. (or about $186.7 mil. at current exchange rates) in cash and assumption of about [pound]23 mil. (or about $35.2 mil.) in debt. The final deal given antitrust clearance excludes "substantially all of the mass spectrometer businesses of Fisions and a high-resolution mass spectrometer/ICP product," Thermo states. The firm had inked a deal to buy all of the Scientific Instruments Division on March 1 ("The Gray Sheet" Sept. 4, 1995, p. 4). The portion of the SID business acquired represents about 80% of 1995 revenues of approximately, [pound]286 mil. (or about $437.6 mil.) and includes analytical instruments used in industrial and research labs...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel